Patents by Inventor Francisco J. Esteva

Francisco J. Esteva has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIAGNOSTIC AND THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING PTEN AND BREAST CANCER
    Publication number: 20190360057
    Abstract: Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
    Type: Application
    Filed: June 18, 2019
    Publication date: November 28, 2019
    Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Dihua Yu, Xiaoyan Zhou, Yoichi Nagata, Francisco J. Esteva, Aysegul A. Sahin
  • Diagnostic and therapeutic methods and compositions involving PTEN and breast cancer
    Patent number: 10378058
    Abstract: Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: August 13, 2019
    Assignee: Board of Regents of The University of Texas System
    Inventors: Dihua Yu, Xiaoyan Zhou, Yoichi Nagata, Francisco J. Esteva, Aysegul A. Sahin
  • DIAGNOSTIC AND THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING PTEN AND BREAST CANCER
    Publication number: 20140112917
    Abstract: Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
    Type: Application
    Filed: October 11, 2013
    Publication date: April 24, 2014
    Inventors: Dihua Yu, Xiaoyan Zhou, Yoichi Nagata, Francisco J. Esteva, Aysegul A. Sahin
  • METHODS AND COMPOSITIONS FOR PREDICTING CANCER THERAPY RESPONSE
    Publication number: 20130005592
    Abstract: The invention generally relates to molecular diagnostics, and particularly to molecular markers for cancer therapy response and methods of use thereof.
    Type: Application
    Filed: September 10, 2010
    Publication date: January 3, 2013
    Applicants: Board of Regents of the University of Texas System, Myriad Genetics Incorporated
    Inventors: Steven Stone, Alexander Gutin, Darl Flake, Francisco J. Esteva, Dihua Yu
  • DIAGNOSTIC AND THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING PTEN AND BREAST CANCER
    Publication number: 20120039875
    Abstract: Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
    Type: Application
    Filed: July 15, 2011
    Publication date: February 16, 2012
    Applicant: Board of Regents of The University of Texas System
    Inventors: Dihua Yu, Xiaoyan Zhou, Yoichi Nagata, Francisco J. Esteva, Aysegul A. Sahin
  • Diagnostic and therapeutic methods and compositions involving PTEN and breast cancer
    Patent number: 7981618
    Abstract: Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
    Type: Grant
    Filed: November 5, 2004
    Date of Patent: July 19, 2011
    Assignee: Board of Regents of The University of Texas System
    Inventors: Dihua Yu, Xiaoyan Zhou, Yoichi Nagata, Francisco J. Esteva, Aysegul A. Sahin
  • DIAGNOSTIC AND THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING PTEN AND BREAST CANCER
    Publication number: 20110150868
    Abstract: Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
    Type: Application
    Filed: November 10, 2010
    Publication date: June 23, 2011
    Applicant: Board of Regents of The University of Texas System
    Inventors: Dihua Yu, Xiaoyan Zhou, Yoichi Nagata, Francisco J. Esteva, Aysegul A. Sahin